S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
S&P 500   4,248.81 (+0.46%)
DOW   33,025.42 (+0.07%)
QQQ   358.53 (+1.02%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
NASDAQ:ACST

Acasti Pharma (ACST) News Today

$2.66
0.00 (0.00%)
(As of 12:39 PM ET)
Compare
Today's Range
$2.64
▼
$2.78
50-Day Range
$1.75
▼
$2.95
52-Week Range
$1.72
▼
$5.05
Volume
33,037 shs
Average Volume
31,565 shs
Market Capitalization
$19.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.70
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media
SourceHeadline
finance.yahoo.com logoAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
finance.yahoo.com - October 4 at 10:40 AM
MarketBeat logoShort Interest in Acasti Pharma Inc. (NASDAQ:ACST) Decreases By 22.8%
americanbankingnews.com - September 30 at 3:22 AM
MarketBeat logoAcasti Pharma Inc. (NASDAQ:ACST) Director Buys $1,251,286.35 in Stock
americanbankingnews.com - September 29 at 5:44 AM
seekingalpha.com logoAcasti announces $7.5M private placement equity funding
seekingalpha.com - September 27 at 1:55 PM
MarketBeat logoAcasti Pharma (NASDAQ:ACST) Share Price Passes Below Two Hundred Day Moving Average of $2.69
americanbankingnews.com - September 26 at 3:44 AM
markets.businessinsider.com logoAnalysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)
markets.businessinsider.com - July 12 at 7:00 AM
marketbeat.com logo
marketbeat.com - July 10 at 10:28 AM
markets.businessinsider.com logoAcasti Pharma: Reverse Stock Split To Become Effective July 10
markets.businessinsider.com - July 7 at 8:48 AM
finance.yahoo.com logoAcasti Pharma Announces 1-for-6 Reverse Stock Split
finance.yahoo.com - July 7 at 8:48 AM
finance.yahoo.com logoAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
finance.yahoo.com - July 5 at 1:57 PM
msn.com logoRecap: Acasti Pharma Q4 Earnings
msn.com - June 23 at 9:34 AM
finance.yahoo.com logoWe're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely
finance.yahoo.com - May 10 at 9:21 AM
finance.yahoo.com logoAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
finance.yahoo.com - May 8 at 11:11 AM
finance.yahoo.com logoAcasti Announces Appointment of Prashant Kohli as CEO
finance.yahoo.com - April 4 at 9:53 AM
finance.yahoo.com logoAcasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
finance.yahoo.com - April 4 at 9:53 AM
finance.yahoo.com logoWhen Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?
finance.yahoo.com - March 30 at 10:16 AM
finance.yahoo.com logoAcasti Pharma Inc. Announces the Resignation of a Director
finance.yahoo.com - March 30 at 10:16 AM
finance.yahoo.com logoAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
finance.yahoo.com - March 13 at 8:09 AM
msn.com logoAcasti Pharma's Earnings Outlook
msn.com - February 13 at 10:44 AM
finance.yahoo.com logoAcasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
finance.yahoo.com - February 7 at 9:52 AM
finance.yahoo.com logoAcasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
finance.yahoo.com - January 25 at 12:31 PM
finance.yahoo.com logoAcasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
finance.yahoo.com - January 17 at 9:46 AM
finance.yahoo.com logoAcasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
finance.yahoo.com - January 5 at 10:03 AM
markets.businessinsider.com logoH.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)
markets.businessinsider.com - December 29 at 8:20 AM
finance.yahoo.com logoAcasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript
finance.yahoo.com - December 29 at 8:20 AM
finance.yahoo.com logoAcasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
finance.yahoo.com - December 28 at 8:39 AM
finance.yahoo.com logoAcasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
finance.yahoo.com - December 22 at 12:23 PM
financialpost.com logoAcasti Pharma Reports Second Quarter 2023 Operational Results
financialpost.com - November 14 at 7:14 AM
finance.yahoo.com logoAcasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
finance.yahoo.com - November 8 at 9:17 AM
finance.yahoo.com logoAcasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
finance.yahoo.com - September 29 at 11:41 AM
finance.yahoo.com logoAcasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast
finance.yahoo.com - September 21 at 12:05 PM
finance.yahoo.com logoAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
finance.yahoo.com - September 13 at 8:27 AM
theglobeandmail.com logoAcasti Pharma: Top 10 Undervalued Healthcare Stocks on TSX Venture Exchange (ACST)
theglobeandmail.com - September 10 at 9:11 PM
finance.yahoo.com logoEdited Transcript of ACST.V earnings conference call or presentation 11-Aug-22 5:00pm GMT
finance.yahoo.com - August 25 at 9:22 PM
seekingalpha.com logoAcasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 5:57 PM
finance.yahoo.com logoAcasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022
finance.yahoo.com - August 2 at 5:57 PM
stockhouse.com logoAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia
stockhouse.com - July 29 at 4:48 AM
finance.yahoo.com logoAcasti Pharma Reports Fiscal Year 2022 Operational Results
finance.yahoo.com - June 21 at 8:23 AM
finance.yahoo.com logoAcasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call
finance.yahoo.com - June 16 at 5:47 PM
seekingalpha.com logoAcasti gets patents related to brain hemorrhage drug GTX-104, pain therapy GTX-101
seekingalpha.com - June 14 at 10:47 AM
finance.yahoo.com logoAcasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101
finance.yahoo.com - June 14 at 10:47 AM
finance.yahoo.com logoAcasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine
finance.yahoo.com - May 18 at 3:32 PM
seekingalpha.com logoAcasti says pharmacokinetic trial for lead asset met all study goals
seekingalpha.com - May 18 at 10:00 AM
finance.yahoo.com logoAcasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints
finance.yahoo.com - May 18 at 10:00 AM
stockhouse.com logoUpdate: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18th
stockhouse.com - May 17 at 1:58 PM
finanznachrichten.de logoAcasti Pharma Inc.: Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18th
finanznachrichten.de - May 16 at 3:59 PM
finance.yahoo.com logoUpdate: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th
finance.yahoo.com - May 16 at 3:59 PM
finanznachrichten.de logoAcasti Pharma Inc.: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
finanznachrichten.de - May 12 at 12:54 PM
finance.yahoo.com logoAcasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
finance.yahoo.com - May 12 at 12:54 PM
finance.yahoo.com logoAcasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th
finance.yahoo.com - April 25 at 3:00 PM
Get Acasti Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.



ACST Media Mentions By Week

ACST Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACST
News Sentiment
▼
0.93

0.50
▲
Average
Medical
News Sentiment

ACST News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACST Articles
This Week
▼
5

0
▲
ACST Articles
Average Week

Get Acasti Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ACST) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -